News

Show
news from

Achilles reports Q3 2022 Financial Results and Business Highlights

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

Third Quarter Update FY2022/3

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

Autolus Therapeutics announces Board changes

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

Load more

Search